A pharmaceutical study on the application of nanotechnology to enhance the delivery of a certain drug / (Record no. 170649)
[ view plain ]
| 000 -LEADER | |
|---|---|
| fixed length control field | 10216namaa22004331i 4500 |
| 003 - CONTROL NUMBER IDENTIFIER | |
| control field | OSt |
| 005 - أخر تعامل مع التسجيلة | |
| control field | 20250223033427.0 |
| 008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION | |
| fixed length control field | 250206s2024 |||a|||fr|m|| 000 0 eng d |
| 040 ## - CATALOGING SOURCE | |
| Original cataloguing agency | EG-GICUC |
| Language of cataloging | eng |
| Transcribing agency | EG-GICUC |
| Modifying agency | EG-GICUC |
| Description conventions | rda |
| 041 0# - LANGUAGE CODE | |
| Language code of text/sound track or separate title | eng |
| Language code of summary or abstract | eng |
| -- | ara |
| 049 ## - Acquisition Source | |
| Acquisition Source | Deposit |
| 082 04 - DEWEY DECIMAL CLASSIFICATION NUMBER | |
| Classification number | 615.1 |
| 092 ## - LOCALLY ASSIGNED DEWEY CALL NUMBER (OCLC) | |
| Classification number | 615.1 |
| Edition number | 21 |
| 097 ## - Degree | |
| Degree | Ph.D |
| 099 ## - LOCAL FREE-TEXT CALL NUMBER (OCLC) | |
| Local Call Number | Cai01.08.08.Ph.D.2024.Me.P |
| 100 0# - MAIN ENTRY--PERSONAL NAME | |
| Authority record control number or standard number | Mennatullah Magdy Ibrahim Mohamed, |
| Preparation | preparation. |
| 245 12 - TITLE STATEMENT | |
| Title | A pharmaceutical study on the application of nanotechnology to enhance the delivery of a certain drug / |
| Statement of responsibility, etc. | by Mennatullah Magdy Ibrahim Mohamed ; Under the supervision of Prof. Dr. Mohamed Ahmed El-Nabarawi, Prof. Dr. Emad Basalious Bashir, Prof. Dr. Amal Ibrahim Makhlouf. |
| 246 15 - VARYING FORM OF TITLE | |
| Title proper/short title | دراسة صيدلية على تطبيق تقنية النانو لتحسين توصيل عقار معين / |
| 264 #0 - PRODUCTION, PUBLICATION, DISTRIBUTION, MANUFACTURE, AND COPYRIGHT NOTICE | |
| Date of production, publication, distribution, manufacture, or copyright notice | 2024. |
| 300 ## - PHYSICAL DESCRIPTION | |
| Extent | 110 pages : |
| Other physical details | illustrations ; |
| Dimensions | 25 cm. + |
| Accompanying material | CD. |
| 336 ## - CONTENT TYPE | |
| Content type term | text |
| Source | rda content |
| 337 ## - MEDIA TYPE | |
| Media type term | Unmediated |
| Source | rdamedia |
| 338 ## - CARRIER TYPE | |
| Carrier type term | volume |
| Source | rdacarrier |
| 502 ## - DISSERTATION NOTE | |
| Dissertation note | Thesis (Ph.D)-Cairo University, 2024. |
| 504 ## - BIBLIOGRAPHY, ETC. NOTE | |
| Bibliography, etc. note | Bibliography: pages 96-110. |
| 520 ## - SUMMARY, ETC. | |
| Summary, etc. | This work aimed at the achievement of targeted nose-to-brain delivery of mirtazapine (MZP) for depression treatment using nanosystems which have always been recognized as a milestone in the development of directed drug carrier systems to the brain. The intranasal route has proven to be a reliable and promising route for delivering therapeutics to the central nervous system (CNS). <br/>Hence, the work in this thesis was divided into three chapters:<br/>Chapter I<br/>Formulation and optimization of mirtazapine loaded lipid nanocapsules<br/>The aim of this chapter was to prepare and evaluate mirtazapine loaded lipid nanocapsules (MZP-LNCs). MZP-loaded LNCs were analyzed and optimized by D optimal mixture design. The optimized formula suggested by the software was prepared using 10 % labrafac, 50 % solutol and 40 % water. The measured dependent variables were 20.59 nm for PS, 0.223 for PDI, -5.71 for ZP and 7.21 mg/g for SC, which were in great accordance to the predicted values suggested by the software. TEM photomicrographs of the optimized MZP-LNCs revealed a spherical structure with no aggregation. The optimized MZP-LNCs release profile was characterized by a slower release rate than MZP aqueous dispersion. Upon storage at 4 °C for 3 months, the physical appearance of the optimum formula did not change. It can be concluded that the optimum formula suggested by D optimal mixture design might be considered as a promising LNCs formula; therefore, it was selected for further investigations.<br/>Chapter II<br/>Formulation and optimization of mirtazapine loaded pluronics modified liposomes<br/>The aim of this chapter was to prepare and evaluate mirtazapine loaded pluronics modified liposomes (MZP-PMLs). MZP-loaded PMLs were analyzed and optimized by Box-Behnken design. The optimized formula suggested by the software was prepared using 100 mg PC, 75 mg pluronics and 28 mg tween. The measured dependent variables were 103.78 nm for PS, 0.577 for PDI, -33.21 for ZP and 99.03 % for SE, which were in great accordance to the predicted values suggested by the software. The optimized PMLs showed two different particle sizes when measured by zeta sizer which indicate the formation of mixed micelles with the stealth liposomes due to presence of pluronics. TEM photomicrographs of the optimized MZP-PMLs revealed a spherical structure with no aggregation and size range correlating with that obtained by zeta sizer. The optimized MZP-PMLs release profile was characterized by a slower release rate than MZP aqueous dispersion. Upon storage at 4 °C for 3 months, the physical appearance of the optimum formula did not change.It can be concluded that the optimum formula suggested by Box-Behnken design might be considered as a promising PMLs formula; therefore, it was selected for further investigations.<br/>Chapter III<br/>Radiolabeling, in vivo biodistribution and pharmacokinetic study of the optimized MZP-LNCs & optimized MZP-PMLs<br/>The ability of the chosen prepared MZP-LNCs and MZP-PMLs to directly deliver the drug to the brain was investigated utilizing biodistribution technique. Radioiodination of MZP was utilized in the biodistribution study. The pharmacokinetic behavior of intranasal (IN) radioiodinated MZP-LNCs (131I-MZP-LNCs) and radioiodinated MZP-PMLs (131I-MZP-PMLs) in brain and blood was compared with radioiodinated MZP solution after intravenous (IV) and intranasal administration in mice. Based on the results of the in vivo study, the intranasal administration of MZP-LNCs and MZP-PMLs had achieved significant enhancement in the brain availability of the drug and enhanced brain drug targeting. As a final conclusion, intranasal administration of MZP-LNCs and MZP-PMLs may be considered as a promising non-invasive approach for successful treatment of depression.<br/> |
| 520 ## - SUMMARY, ETC. | |
| Summary, etc. | يهدف هذا البحث الي توصيل الميرتازابين باستخدام الغشاء المخاطى المبطن للانف مباشرة للجهاز العصبى المركزى وذلك عن طريق تحضير كبسولات نانومترية دهنية و المحملة بالعقار و تحضيرحويصلات نانونية مثل الليبوزومات. وسوف يتم تجربتها علي حيوانات تجارب (فئران) لتقدير كفاءتها وسلامتها.<br/>لهذا تنقسم الدراسة فى هذه الرسالة الى ثلاثة فصول:<br/>الفصل الأول: صياغة واستمثال كبسولات نانومترية دهنية محملة بالميرتازابين <br/>الفصل الثانى: صياغة واستمثال حويصلات بيلوزومية معدلة محملة بالميرتازابين<br/>الفصل الثالث: وضع العلامات الإشعاعية ودراسة التوزيع البيولوجى والحركية الدوائية للصيغة المثلى لكل من الكبسولات النانومترية الدهنية و الحويصلات المعدلة المحملة بالميرتازابين <br/>الفصل الأول: صياغة واستمثال كبسولات نانومترية دهنية محملة بالميرتازابين <br/>يهدف هذا الفصل الي صياغه كبسولات نانومترية دهنية تحتوي علي عقار الميرتازابين وقد تم إتباع التصميم الاحصائى D optimal mixture design. وتم تحضير الصيغة الأفضل المقترحة إحصائيا ٌ وكان حجم الجسيمات لها 20.59 نانوميتر وجهد زيتا 5.71 - ومؤشر التشتت المتعدد 0.223 وقدرة الاذابة 7.21ميللىجرام/جرام. هذا و قد تعرضت هذه الصيغة لمزيد من الأختبارات الممثلة فى الفحص الميكروسكوبى TEM وقياس نسبة الثبات وبناء على النتائج تم اختيار هذه الصيغة لمزيد من الدراسات. <br/>الفصل الثانى: صياغة واستمثال حويصلات بيلوزومية معدلة محملة بالميرتازابين<br/>يهدف هذا الفصل الي صياغه حويصلات بيلوزومية معدلة تحتوي علي عقار الميرتازابين وقد تم إتباع التصميم الاحصائى Box Behnken design وتم تحضير الصيغة الأفضل المقترحة إحصائيا ٌ. وكان حجم الجسيمات 103.8 نانوميتر وجهد زيتا 33.21- ومؤشر التشتت المتعدد 0.577 وقدرة الاذابة99% . هذا و قد تعرضت هذه الصيغة لمزيد من الأختبارات الممثلة فى الفحص الميكروسكوبى TEM وقياس نسبة الثبات وبناء على النتائج تم اختيار هذه الصيغة لمزيد من الدراسات. <br/><br/>الفصل الثالث: وضع العلامات الإشعاعية ودراسة التوزيع البيولوجى والحركية الدوائية للصيغة المثلى لكل من الكبسولات النانومترية الدهنية و الحويصلات المعدلة المحملة بالميرتازابين<br/>تم إختيار الصيغة MZP-LNCs و الصيغه MZP-PMLsلتقييم اتاحتهما الحيوية فى المخ ومقارنتهما بمحلول الميرتازابين وذلك باستخدام فئران نجارب .فتم توسيم جزئ الميرتازابين نوويا واستخدام العقار المشع لتحضير الصيغة الأفضل من الكبسولات النانومترية الدهنية MZP-LNCs و الحويصلات المعدلة MZP-PMLs وقد اثبتت النتائج قدرة الصيغ المثلى MZP-LNCs و MZP-PMLs على توصيل العقاربنسبة أعلى للمخ وبمستويات قليلة فى الدم عند تناولها عن طريق الانف وذلك مقارنة بمحلول العقارعند اعطائه للفئران بالحقن الوريدى وعن طريق الانف. وبالتالى يمكن أن نستنتج من هذه الدراسة أن تناول الكبسولات النانومترية الدهنية و الحويصلات البيلوزومية المعدلة المحملة بالميرتازابين تعتبر طريقة ايجابية مناسبة لتعزيز استهداف العقار للمخ عن طريق الانف<br/> |
| 530 ## - ADDITIONAL PHYSICAL FORM AVAILABLE NOTE | |
| Issues CD | Issued also as CD |
| 546 ## - LANGUAGE NOTE | |
| Text Language | Text in English and abstract in Arabic & English. |
| 650 #7 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Drugs |
| Source of heading or term | qrmak |
| 653 #0 - INDEX TERM--UNCONTROLLED | |
| Uncontrolled term | Mirtazapine |
| -- | intranasal |
| -- | lipid nanocapsules |
| -- | brain |
| -- | 131I |
| -- | modified liposomes |
| -- | depression |
| 700 0# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Mohamed Ahmed El-Nabarawi |
| Relator term | thesis advisor. |
| 700 0# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Emad Basalious Bashir |
| Relator term | thesis advisor. |
| 700 0# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Amal Ibrahim Makhlouf |
| Relator term | thesis advisor. |
| 900 ## - Thesis Information | |
| Grant date | 01-01-2024 |
| Supervisory body | Mohamed Ahmed El-Nabarawi |
| -- | Emad Basalious Bashir |
| -- | Amal Ibrahim Makhlouf |
| Universities | Cairo University |
| Faculties | Faculty of Pharmacy |
| Department | Department of Pharmaceutics and Industrial Pharmacy |
| 905 ## - Cataloger and Reviser Names | |
| Cataloger Name | Eman Ghareeb |
| Reviser Names | Huda |
| 942 ## - ADDED ENTRY ELEMENTS (KOHA) | |
| Source of classification or shelving scheme | Dewey Decimal Classification |
| Koha item type | Thesis |
| Edition | 21 |
| Suppress in OPAC | No |
| Source of classification or shelving scheme | Home library | Current library | Date acquired | Inventory number | Full call number | Barcode | Date last seen | Effective from | Koha item type |
|---|---|---|---|---|---|---|---|---|---|
| Dewey Decimal Classification | المكتبة المركزبة الجديدة - جامعة القاهرة | قاعة الرسائل الجامعية - الدور الاول | 06.02.2025 | 90527 | Cai01.08.08.Ph.D.2024.Me.P | 01010110090527000 | 06.02.2025 | 06.02.2025 | Thesis |